Marshall Wace North America’s Y-mAbs Therapeutics YMAB Stock Holding History

Marshall Wace North America’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,204	Closed	-$277K	–	1760
2021 Q2	$277K	Buy	+8,204	New	+$263K	﹤0.01%	1295
2020 Q4	–	Sell	-12,207	Closed	-$469K	–	1630
2020 Q3	$469K	Buy	+12,207	New	+$486K	﹤0.01%	976
2020 Q2	–	Sell	-3,924	Closed	-$102K	–	1534
2020 Q1	$102K	Buy	+3,924	New	+$114K	﹤0.01%	995
2019 Q2	–	Sell	-735	Closed	-$19K	–	1675
2019 Q1	$19K	Sell	735 -38,448	-98%	-$844K	﹤0.01%	1392
2018 Q4	$797K	Buy	+39,183	New	+$900K	0.01%	666

Other funds holding YMAB

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Marshall Wace North America's YMAB Position: Q3 2021 in Review

Marshall Wace North America sold out of Y-mAbs Therapeutics (YMAB) in Q3 2021, closing a stake of 8,204 shares — an estimated $277K sold.

Marshall Wace North America first reported a position in YMAB in Q4 2018 and held it in 5 quarters. The position peaked at $797K in Q4 2018. 97 funds tracked by Wall St. Rank hold YMAB as of Q3 2021.

Marshall Wace North America reported no remaining Y-mAbs Therapeutics position as of Q3 2021 after selling out during the quarter.
Marshall Wace North America sold 8,204 Y-mAbs Therapeutics shares in Q3 2021, an estimated $277K.
Marshall Wace North America first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 5 quarters.
Marshall Wace North America's Y-mAbs Therapeutics position peaked at $797K in Q4 2018.
97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.